Liabilities / Assets
53rd percentile
Higher debt load relative to assets than 53% of similar nonprofits.
Neuroendocrine Tumor Research Foundation
990 • Fiscal year 2017 • EIN 20-1945347
Siviq Scores
Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.
0.24x
Liabilities / Revenue
87th percentile
Higher debt load relative to revenue than 87% of similar nonprofits.
Net Margin
2nd percentile
Higher net margin than 2% of similar nonprofits.
Top Officer Pay
Score unavailable
This filing does not contain officer compensation rows.
Asset Growth
23rd percentile
Faster asset growth than 23% of similar nonprofits.
Revenue Growth
52nd percentile
Faster revenue growth than 52% of similar nonprofits.
Balance Sheet
Assets
Down$18,814,091
Down $413,034 (-2.1%) from 2016
Net Assets
Down$14,322,180
Down $3,423,873 (-19%) from 2016
Liabilities
Up$4,491,911
Up $3,010,839 (+203%) from 2016
Revenue And Expenses
Revenue
Up$2,292,536
Up $113,961 (+5.2%) from 2016
Expenses
Up$6,307,127
Up $4,206,918 (+200%) from 2016
Net Income
Down-$4,014,591
Down $4,092,957 (-5223%) from 2016
Historical Trend
Filing Detail Status
This 2017 filing currently has summary financial data only. Detailed schedules, leadership, and program rows are not available for this filing yet.
Jump To
Filing Snapshot
- Filing Period
- Jan 1, 2017 to Dec 31, 2017
Mission and Program Overview
Mission
To fund research to discover cures & more effective treatments for neuroendocrine cancers. The NET Research Foundation is committed to improving the lives of those affected by neuroendocrine cancer by providing information & educational resources.
Document Assets
No mirrored PDF or thumbnail assets are attached yet.
Filings
Displayed year
2017 • Form 990Summary only. Only limited summary data is available for this year.
- Assets
- $18,814,091
- Liabilities
- $4,491,911
- Net assets
- $14,322,180
- Revenue
- $2,292,536
- Expenses
- $6,307,127
- Net income
- -$4,014,591